William Blair analyst Sarah Schram has reiterated their bullish stance on XENE stock, giving a Buy rating yesterday.
Sarah Schram’s rating is based on Xenon’s strategic advancements and promising pipeline developments. The company is on track with its X-TOLE2 program, expecting top-line data in the second half of 2025, which reinforces confidence in its potential as a frontline treatment option for epilepsy. The once-daily dosing and lack of titration for azetukalner make it a compelling alternative to existing treatments, potentially positioning it ahead of competitors like SK Biopharmaceutical’s Xcopri, which has a more complex dosing regimen.
Furthermore, Xenon’s expansion into bipolar disorder-related depression with two planned Phase III clinical studies highlights its innovative approach and commitment to addressing unmet medical needs. The genetic and preclinical rationale for targeting Kv7 channels, along with positive data from a Phase II study in major depressive disorder, supports the potential success of this new venture. These factors collectively underpin Sarah Schram’s Buy rating for Xenon, indicating strong growth prospects and a robust development strategy.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XENE in relation to earlier this year.